TG Therapeutics, Inc. and MiMedx Group, Inc.: A Comprehensive Revenue Analysis

Biotech Revenue Trends: A Decade of Growth and Breakthroughs

__timestamp	MiMedx Group, Inc.	TG Therapeutics, Inc.
Wednesday, January 1, 2014	118223000	152381
Thursday, January 1, 2015	187296000	152381
Friday, January 1, 2016	245015000	152381
Sunday, January 1, 2017	321139000	152381
Monday, January 1, 2018	359111000	152000
Tuesday, January 1, 2019	299255000	152000
Wednesday, January 1, 2020	248234000	152000
Friday, January 1, 2021	258615000	6689000
Saturday, January 1, 2022	267841000	2785000
Sunday, January 1, 2023	321477000	233662000

Cracking the code

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, MiMedx Group, Inc. and TG Therapeutics, Inc. have showcased contrasting revenue trajectories. MiMedx Group, Inc. has experienced a steady climb, with revenues peaking in 2018 at approximately 360 million, before stabilizing around 320 million in 2023. This represents a robust 170% increase from 2014. In contrast, TG Therapeutics, Inc. saw minimal revenue until a significant surge in 2023, reaching nearly 234 million, a staggering 153,000% increase from its 2014 figures. This dramatic rise highlights TG Therapeutics' breakthrough in the market. These trends underscore the volatile yet promising nature of the biotech industry, where innovation can lead to exponential growth.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025